Navigation
banner

Cancer Therapeutics & Partnering Summit 2017

2017-12-132017-08-282017-07-28
Register 3 for the price of 2 with the coupon code rcdvb!


registration button

Subscribe for updates




Dear Colleague,

We invite you to attend the 6th Cancer Therapeutics & Partnering Summit, to be held on September 28-29, 2017 in San Diego, CA. This summit includes three tracks focused on both the research, and business perspectives in oncology.

This summit will continue to be a premier event for translational researchers, preclinical scientists and managers, and those carrying out early phase clinical trials working to identify and exploit advances in the field of oncology in order to deliver products with a meaningful clinical impact. In addition, industry leaders from big pharma and various biotech/pharmaceutical companies, including business/corporate development executives, licensing executives, global alliance, and venture capitalists, will all be present to explore potential collaborations and learn about relevant issues in oncology.

Focus areas include cancer diagnostics, cancer immunotherapy, as well as partnering and deal-making in oncology. Discussion topics include emerging targets, therapeutic strategies, next generation sequencing in cancer diagnosis, progress in cancer immunotherapy, combination strategies in immuno-oncology, advancements in technology, as well as business development trends, markets, partnership opportunities, and access to capital market.

Both cutting-edge researchers and those who guide its commercial development will be on-hand to share their knowledge and insights as to how therapeutic cancer targets are identified, and how this research translates into meaningful therapeutics that benefit patients living with cancer!

Session Topics:

Joint Plenary Sessions:
I. Opening Keynote Session – Historical Perspective & Current State of the Industry
II. Round Table Discussions
III. Breakfast with Mentors from Academia & Industry
IV. Award Ceremony & Closing Keynote Session – Predictions for the Future

Complementary & Companion Diagnostics in Oncology
I. Technologies and Biomarkers
II. Case Studies for Development and Commercialization

Cancer Immunotherapy
I. Precision Medicine and Immunomodulatory Antibodies
II. Combination Immunotherapy and Novel Targets

Oncology Partnering & Deal-Making
I. What’s New in Oncology – Targets, Models, Assays
II. Partnering between Pharma, Biotech, Academic Groups and CROs to Advance Research
III. Oncology Perspectives from Venture Capital & Public Markets
IV. Technology Transfer & Licensing: Challenges & Opportunities

 

We hope to see you there!

Best regards,

The 2017 Advisory Committee

 

2017 Program Director
Saikat Nandi, Cold Spring Harbor Laboratory
2017 Advisory Board Members
Tullia Bruno, University of Pittsburgh
Angela Thomas, Edinburgh Haemophilia Centre
Kamala Maddali, Cancer Genetics Incorporated
Alan Epstein, University of Southern California
Charles Theuer, TRACON Pharmaceuticals
Satish Medicetty, GTCbio